Table 3

Clinical outcomes at 24 months for patients with moderately-severe AS and severe AS

Moderately-severe AS (n=113)Severe AS (n=1301)
TAVR (n=66)SAVR (n=47)P valueTAVR (n=664)SAVR (n=637)P value
All-cause mortality or disabling stroke5 (7.7)3 (6.5)0.8226 (4.0)39 (6.3)0.05
All-cause mortality3 (4.6)2 (4.4)0.9522 (3.3)27 (4.4)0.32
Reintervention1 (1.5)0 (0.0)0.405 (0.8)5 (0.8)0.91
All stroke and TIA8 (12.6)2 (4.3)0.1552 (7.9)49 (8.0)0.99
Bleed6 (9.5)3 (6.4)0.6270 (10.6)88 (14.0)0.05
Life-threatening or disabling3 (4.7)2 (4.3)0.9628 (4.2)61 (9.7)<0.001
Major bleed3 (4.8)1 (2.1)0.4942 (6.4)33 (5.3)0.42
Major vascular complication2 (3.0)1 (2.1)0.7726 (3.9)23 (3.6)0.78
Acute kidney injury2 (3.0)5 (10.6)0.1013 (2.0)64 (10.1)<0.001
Myocardial infarction1 (1.6)2 (4.3)0.3715 (2.3)9 (1.4)0.27
Valve endocarditis0 (0.0)0 (0.0)NA3 (0.5)6 (1.0)0.26
Valve thrombosis1 (1.5)0 (0)0.401 (0.2)1 (0.2)0.96
Valve thrombosis (subclinical)0 (0.0)0 (0.0)NA4 (0.6)3 (0.5)0.78
Permanent pacemaker implant*19 (30.1)1 (2.1)<0.001134 (20.3)52 (8.3)<0.001
Permanent pacemaker implant†19 (30.5)1 (2.3)<0.001134 (21.0)52 (8.6)<0.001
Atrial fibrillation6 (9.2)14 (29.9)0.00379 (12.0)255 (40.3)<0.001
Coronary artery obstruction1 (1.5)0 (0.0)0.405 (0.8)2 (0.3)0.28
Composite event‡9 (13.8)4 (8.7)0.4261 (9.2)102 (16.2)<0.001
  • Data shown as number of patients with an event (%), where Kaplan-Meier estimates are provided as percentages. The corresponding p values were calculated by the log-rank test for all data through 24 months.

  • *Subjects with pacemaker or implantable cardioverter defibrillator (ICD) at baseline are included.

  • †Subjects with pacemaker or ICD at baseline are excluded.

  • ‡Composite event includes all-cause mortality, disabling stroke, life threatening or disabling bleeding, major vascular complication, acute kidney injury stage 2 or 3.

  • AS, aortic stenosis; NA, not available; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TIA, transient ischaemic attack.